LENZ Therapeutics, Inc. (LENZ) Financial Statements
LENZ Therapeutics, Inc. (LENZ) reported trailing twelve-month revenue of $21.5M (up 134.6% year on year) and net income of -$126.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$114.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LENZLENZ Therapeutics, Inc.Follow LENZ — free
—
Price chart with a free account
- Market cap
- 99.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Revenue | 19.1 | 21.5 | |
| Gross profit | 18.7 | — | |
| Research & development | 18.7 | 3.8 | |
| Operating income | -91.1 | -135.7 | |
| Pre-tax income | -81.6 | -126.0 | |
| Income tax | 0.5 | 0.0 | |
| Net income | -82.1 | -126.0 | |
| Diluted EPS ($) | -2.85 | -4.13 | |
| Diluted shares (mn) | 28.8 | — |
USD millions · SEC XBRL
LENZ Therapeutics, Inc. — questions
- What is LENZ Therapeutics, Inc.'s revenue?
- $21.5M over the twelve months to 2026-06-30, up 134.6% year on year, from its 10-Q and 10-K filings.
- What is LENZ Therapeutics, Inc.'s net income?
- -$126.0M over the twelve months to 2026-06-30.
- What is LENZ Therapeutics, Inc.'s free cash flow?
- -$114.4M over the twelve months to 2026-06-30.
- What are LENZ Therapeutics, Inc.'s diluted earnings per share?
- $-4.13 over the twelve months to 2026-06-30.
Every figure on this page comes from LENZ Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.